

DO NOT USE FOR TRADEMARKS

BOX ASSIGNMENTS

RECORDATION FORM COVER SHEET
PATENT APPLICATIONS & PATENTS ONLYTO THE DIRECTOR OF THE US PATENT AND TRADEMARK OFFICE:
SIR: PLEASE RECORD THE ATTACHED ORIGINAL DOCUMENTS OR COPY THEREOF.

1. NAME OF CONVEYING PARTY(IES) (ASSIGNORS(S)):

1. Idec Pharmaceuticals Corporation

2. Seikagaku Corporation

3.

4.

5.

6.

7.

8.

ADDITIONAL NAME(S) OF CONVEYING PARTY(IES) ATTACHED? ☐ YES ☒ NO

2. PARTY(IES) (ASSIGNEE(S)) RECEIVING INTEREST:

NAME: Biogen Idec MA Inc.

ADDRESS: 14 Cambridge Center, Cambridge MA 02142

ADDITIONAL NAME(S) & ADDRESS(ES) ATTACHED? ☐ YES ☒ NO

3. NATURE OF CONVEYANCE (DOCUMENT):

(Submit herewith only one document for recordation—multiple copies of same Assignment signed by different inventors is one document)☒ ASSIGNMENT OF ☒ WHOLE ☐ PART INTEREST
☐ ORIGINAL ☐ FACSIMILE/PHOTOCOPY
☐ CHANGE OF NAME ☐ VERIFIED TRANSLATION
☐ SECURITY ☐ MERGER ☐ OTHER:

EXEC. DATE: 8/3/04; 7/12/04; 8/3/04

EXECUTION DATE(S) ON THE DECLARATION IF FILED HEREWITH: (NOTE: IF DATES ON DECLARATION AND ASSIGNMENT DIFFER SEE ATTY!)

4.5 APPL. NO.(S) OR PAT NO.(S). OTHERS ON ADDITIONAL SHEET(S) attached? ☐ YES ☒ NO

A. PAT. APP. NO.(S) series code/serial no	M#	1 st INVENTOR if not in item 1	B. PATENT NO(S)	M#	1 st INVENTOR if not in item 1
09/292,053	0275739	Mitchell Reff	6,011,138	0275738	Mitchell Reff
09/019,441	0275470	Mitchell Reff			
10/103,686	0280746	Mitchell Reff			
PCT/US98/02253	0127945	Mitchell Reff			

5. Name & Address of Party to Whom Correspondence
Concerning Document Should be Mailed:Pillsbury Winthrop LLP
Intellectual Property Group
P.O. Box 10500 McLean, VA 22102

6. NUMBER INVOLVED:

APPLNS 4 + PATS 1 = TOTAL = 5

7. AMOUNT OF FEE DUE: (Code 8021)

ABOVE TOTAL x \$40 = \$200

5.5 ATTY DKT: 037003

8. PLEASE CHARGE TO OUR DEPOSIT ACCOUNT

NUMBER: 03-3975

0275738	1997-30-0565	037003	0275738
MATTER NO.	CLIENT REF.	CLIENT NO.	MATTER NO.

dup. sheet not required

9. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

10. Total number of pages including this
cover sheet, attachments and document
(do not file dup. Cover sheet)

4

Signature

Attorney: Thomas A. Cawley, Jr., Ph.D.

Reg. No. 40944

Date: August 17, 2004

Atty/Sec: TAC/JBM:sl

TEL: (703) 905-2144

FAX: (703) 905-2500

FILE WITH PTO RETURN RECEIPT (PAT-103A)

PATENT PAT-114X 9/03

REEL: 015056 FRAME: 0921

700107469

CH \$240.00 033975 09292063

ASSIGNMENT

THIS ASSIGNMENT, by IDEC Pharmaceuticals Corporation, a corporation duly organized under and pursuant to the laws of Delaware, and having its principal place of business at 3030 Callan Road, San Diego, California 92121 and by SEIKAGAKU CORPORATION, a corporation duly organized under and pursuant to the laws of Japan, and having its principal place of business at 2-1-5, Nihonbashi-Honcho, Chuo-Ku, Tokyo Yakugyo Bldg., Tokyo 103, Japan (hereinafter referred to as "the Assignors"), witnesseth:

WHEREAS, the Assignors presently own certain new and useful improvements in **GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS**, which are set forth in each of the national applications identified in Appendix A (attached hereto); and

WHEREAS, Biogen Idec MA Inc., a corporation duly organized under and pursuant to the laws of Massachusetts, and having its principal place of business at 14 Cambridge Center, Cambridge, MA 02142 (hereinafter referred to as "the Assignee"), is desirous of acquiring the entire right, title, and interest in and to all patents and applications identified in Appendix A, and any applications, claiming priority to said application, including provisional applications for Letters Patent of the United States and applications for patent in other countries, and any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon.

NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignors have sold, assigned, transferred, and set over, and by these presents do sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to the inventions for new and useful improvements in **GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS**, which are set forth in each of the national applications identified in Appendix A (attached hereto), the right to file applications on said inventions and the entire right, title, and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said applications, and any and all Letters Patent of the United States of America and all foreign countries that may be granted therefor and thereon, and in and to any and all applications claiming priority to said applications, divisions, continuations, and continuations-in-part of said applications, and reissues and extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignors had this sale and assignment not been made;

AND for the same consideration, the Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignors are the sole and lawful owners of the entire right, title, and interest in and to the inventions set forth in said applications and said applications, including provisional applications, above-mentioned, and that the same are unencumbered, and that the Assignors have good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignors hereby covenant and agree to and with the Assignee, its successors, legal representatives, and assigns that the Assignors will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said inventions or said applications for Letters Patent or Patents, or any proceeding in connection with Letters Patent or Patents for said inventions in any country, including interference proceedings, is lawful and desirable, or that any application claiming priority to said application, division, continuation, or continuation-in-part of any applications for Letters Patent or Patents, or any reissue or extension of any Letters Patent or Patents to be obtained

thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement, and defense of all Letters Patent or Patents for said inventions, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignors hereby request the Commissioner of Patents of the United States Patent and Trademark Office to issue any and all said Letters Patent of the United States to the Assignee as the Assignee of said inventions, the Letters Patent to be issued for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date 8-3-04

Signature of Assignor


IDEC PHARMACEUTICALS
CORPORATION

Date 8-3-04

Signature of Witness




Date July 12, 2004

Signature of Assignor


SEIKAGAKU CORPORATION

Date Aug. 5, 2004

Signature of Witness




Date Aug. 3, 2004

Signature of Assignor


BIOGEN IDEC MA INC.

Date 8/3/04

Signature of Witness



APPENDIX A

<u>Country</u>	<u>Application/Patent No.</u>	<u>Filing/Issue Date</u>
Australia	725482; 61469/98	2/17/98*; 1/25/01
Austria	98906171.8	2/17/98*
Belgium	98906171.8	2/17/98*
Brazil	PI9807437-7	2/17/98*
Canada	2281893	2/17/98*
China	98804345.9	2/17/98*
Denmark	98906171.8	2/17/98*
Europe	98906171.8	2/17/98*
Finland	98906171.8	2/17/98*
France	98906171.8	2/17/98*
Germany	98906171.8	2/17/98*
Great Britain	98906171.8	2/17/98*
Greece	98906171.8	2/17/98*
Hong Kong	00105303.1	8/23/00
Hungary	P0001318	2/17/98*
India	427/DEL/1998	2/19/98
India	484/DEL/2002	4/22/02
Indonesia	W-991061	2/17/98*
Ireland	98906171.8	2/17/98*
Israel	131448	2/17/98*
Israel	159642	12/29/03
Italy	98906171.8	2/17/98*
Japan	10-536675	2/17/98*
Korea (South)	1999-7007604	2/17/98*
Luxembourg	98906171.8	2/17/98*
Malaysia	PI9800732	2/20/98
Mexico	997688	2/17/98*
Monaco	98906171.8	2/17/98*
Netherlands	98906171.8	2/17/98*
New Zealand	337601; 337601	2/17/98*; 9/7/00
Norway	19994006	2/17/98*
Pakistan	136812; 341/99	2/19/98; 4/30/99
Portugal	98906171.8	2/17/98*
PCT	PCT/US98/02253	2/17/98
Philippines	01-1998-00383	2/20/98
Russia	2206614; 99120076	2/17/98*; 6/20/03
Singapore	9903998-4	2/17/98*
South Africa	98/1434; 98/1434	2/20/98*; 10/28/98
Spain	98906171.8	2/17/98*
Sweden	98906171.8	2/17/98*
Switzerland	98906171.8	2/17/98*
Taiwan	87102442	2/20/98
Thailand	042357	2/19/98
United States	08/803,085; 6,011,138	2/20/97; 1/4/00
United States	09/292,053	4/14/99
United States	09/019,441	2/5/98
United States	10/103,686	3/25/02

*International filing date of PCT/US98/02253